Turnstone Biologics Corp. (NASDAQ:TSBX – Get Free Report) saw a significant decrease in short interest in July. As of July 15th, there was short interest totalling 144,700 shares, a decrease of 72.1% from the June 30th total of 519,200 shares. Approximately 1.1% of the company’s shares are short sold. Based on an average trading volume of 137,500 shares, the days-to-cover ratio is presently 1.1 days.
Turnstone Biologics Price Performance
Shares of TSBX traded up $0.04 during midday trading on Friday, hitting $2.55. The stock had a trading volume of 22,032 shares, compared to its average volume of 139,923. The company has a 50 day simple moving average of $2.62 and a two-hundred day simple moving average of $2.80. Turnstone Biologics has a twelve month low of $1.63 and a twelve month high of $13.20. The firm has a market cap of $58.98 million and a price-to-earnings ratio of -0.25.
Turnstone Biologics (NASDAQ:TSBX – Get Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.07). Analysts forecast that Turnstone Biologics will post -3.44 EPS for the current fiscal year.
Institutional Inflows and Outflows
Turnstone Biologics Company Profile
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.
See Also
- Five stocks we like better than Turnstone Biologics
- Do ETFs Pay Dividends? What You Need to Know
- Why Call Options Volume for These 2 Stocks Spiked Together
- How to Use the MarketBeat Excel Dividend Calculator
- MarketBeat Week in Review – 7/22 – 7/26
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.